Union Minister Jitendra Singh stressed that government academia industry collaboration is key to driving scientific progress in India, urging stakeholders to work together in a more connected and practical way to strengthen the country’s innovati...
In a significant development, an advisory panel of the U.S. Food and Drug Administration (FDA) has backed AstraZeneca’s prostate cancer combination therapy in a key vote, strengthening its chances of regulatory approval and offering new hop...
OneSource partners have secured Canada approval, generic semaglutide injection, a major step that could make diabetes treatment more affordable while boosting competition in the rapidly growing GLP-1 drug market.
Takeda Pharmaceutical Company reported new data today showing its Takeda immune drug TAK-881 performs as effectively as an already approved treatment in patients with primary immunodeficiency (PID).
India’s pharmaceutical sector is heading into a mixed March quarter, with drugmakers head into uneven Q4 as margins come under strain from US pricing pressure, loss of high-margin opportunities, and rising costs.
India has launched a nationwide childhood diabetes screening plan, aiming to improve early detection, ensure timely diabetes treatment, and provide long-term child healthcare across the country. The Centre’s new framework focuses on strengtheni...
In a major step forward for healthcare, All India Institute of Medical Sciences (AIIMS Delhi) has rolled out India’s first portable MRI system, bringing bedside brain imaging directly to patients and reshaping how critical care diagnosti...
India’s Revised Safety Norms are set to change how hospitals grow, with the Centre easing long-standing restrictions on building height. The Bureau of Indian Standards (BIS) has removed the 45-metre cap on hospital structures under the newly...
Aurobindo Pharma’s biosimilars arm CuraTeQ Biologics has secured a major regulatory milestone, as it wins Canada nod for its cancer biosimilar, marking a significant step in the company’s global expansion in oncology treatmen...
Bristol Myers beats quarterly profit estimates in its latest earnings report, driven by strong demand for its blood thinner and newer cancer treatments. The company posted adjusted earnings of USD 1.58 per share, topping analyst expectations...
.jpg)
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")